Ventyx Biosciences Investors May Have Legal Claims – VTYX

Investors of Ventyx Biosciences Stock Encouraged to Contact Kehoe Law Firm, P.C. 

VTYX Stock Drops Significantly After Company Reports Termination Of Psoriasis Treatment Study

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or “Ventyx Biosciences”) (NASDAQ: VTYX). 

INVESTORS OF VENTYX BIOSCIENCES STOCK WHO HAVE SUFFERED FINANCIAL LOSSES ARE ENCOURAGED TO CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C.

On November 7, 2023, Investor’s Business Daily reported that “Ventyx Biosciences . . . scrapped a psoriasis drug that didn’t pass muster in Phase 2 testing on Tuesday, sending VTYX stock crashing more than 80%.”

SHAREHOLDERS OF VENTYX WHO HAVE SUFFERED FINANCIAL LOSSES ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE VENTYX SECURITIES INVESTIGATION AND POTENTIAL LEGAL CLAIMS.